drugset / Trial / NCT04773522
A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma
NaSequentialOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and tolerability in Japanese participants with relapsed or refractory multiple myeloma (MM) at the recommended Phase 2 dose (RP2D) identified in NCT03399799 study.
Timeline
- Start
- 2021-05-20
- Primary completion
- 2022-10-14
- Completion
- 2025-09-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Talquetamab | Monoclonal antibody | — | Subcutaneous |